GBA1 and Parkinson disease: Finally, while the small molecules identified in this work may hold therapeutic potential for GBA1-PD, or even sporadic PD [3, 14, 15], our pipeline does not feature assays for quantitation of a PD phenotype, such as α-synuclein aggregation [52].